Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/03/2908166/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
https://www.globenewswire.com/news-release/2024/06/10/2896019/29489/en/AIM-ImmunoTech-to-Participate-in-the-Virtual-Investor-Pitch-Conference.html
https://www.globenewswire.com/news-release/2024/06/03/2892320/29489/en/AIM-ImmunoTech-to-Participate-in-the-Virtual-Investor-Lunch-Break-Series.html
https://www.globenewswire.com/news-release/2024/05/31/2891508/29489/en/AIM-ImmunoTech-Announces-Pricing-of-2-0-Million-Registered-Direct-Offering.html
https://www.globenewswire.com/news-release/2024/05/20/2884917/29489/en/AIM-ImmunoTech-to-Participate-in-Two-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/16/2883292/29489/en/AIM-ImmunoTech-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/09/2878792/29489/en/AIM-ImmunoTech-to-Discuss-First-Quarter-2024-Financial-Results-on-May-16-2024-and-Host-Conference-Call-and-Webcast.html
https://www.globenewswire.com/news-release/2024/05/06/2875832/29489/en/AIM-ImmunoTech-Completes-cGMP-Manufacturing-of-Clinical-Vials-of-Ampligen.html
https://www.globenewswire.com/news-release/2024/04/29/2871258/29489/en/AIM-ImmunoTech-Announces-First-Dose-Level-is-Generally-Well-Tolerated-in-Phase-1b-2-Study-of-Ampligen-and-Imfinzi-as-a-Combination-Therapy-for-Late-Stage-Pancreatic-Cancer.html
https://www.globenewswire.com/news-release/2024/04/25/2869669/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html